A Phase 2/3 interventional study of Misoprostol in Endometrial Polyps in Infertile Patients, sponsored by Henry Aristoteles Mate-Sánez. Completed. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-02-17.
Sponsored by Henry Aristoteles Mate-Sánez · Phase 2/3, Interventional, and Treatment
Endometrial polyps are one of the main causes of infertility in women. In this work we propose an alternative, effective, economical and safe treatment: the use of misoprostol
The prevalence of uterine polyps has been estimated in the general population at 10-15%, while in infertile patients it ranges from 6-32%. Its etiology is considered as multifactorial. Polyps induce a local inflammatory response in the endometrial cavity, causing infertility. The treatment of choice considered "gold standard" is the excision by hysteroscopy, however, improvement has been shown in patients with conservative management due to the regression rate of 27%. There are no recommended drugs to provide a definitive treatment for uterine polyps. Misoprostol is a synthetic analogue derived from prostaglandin E1 that has stimulating effects on the smooth muscle fibers of the uterus, causing contractions of the myometrium, which cause endouterine evacuation. The present study shows a possible utility of misoprostol for the conservative treatment of uterine polyps.
255 studies on the registry are indexed under Uterine Neoplasms; 64 are open to participants now.
This study's enrollment of 54 is above the median of 49 across 181 interventional studies indexed under Uterine Neoplasms.
Browse Uterine Neoplasms studies →This is the only study on the registry with Henry Aristoteles Mate-Sánez as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Misoprostol
Expulsion rate of endometrial polyps
Time frame: 7 days after misoprostol has been applied
Pregnancy rate after expulsion
Time frame: 14-21 days after positive β-human Chorionic Gonadotropin (β-hCG)
The pregnancy rate after expulsion in patients with primary sterility
Time frame: 14-21 days after positive β-hCG
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.